This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through March 4, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the cost of products continues to rise.
3 Reasons to Retain Baxter (BAX) Stock in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Baxter (BAX) due to its strong product portfolio.
CheckCap Ltd. (CHEK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
CheckCap Ltd. (CHEK) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
The Zacks Analyst Blog Highlights ShockWave Medical, CheckCap and Biosig Technologies
by Zacks Equity Research
ShockWave Medical, CheckCap and Biosig Technologies are part of The Zacks top Analyst Blog.
3 Medical Instruments Stocks With Potential to Outperform
by Zacks Equity Research
Here we discuss ShockWave Medical (SWAV), CheckCap (CHEK) and Biosig Technologies (BSGM) that have the potential to outperform their industry going forward.
CheckCap Ltd. (CHEK) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
CheckCap Ltd. (CHEK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
CheckCap Ltd. (CHEK) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
CheckCap Ltd. (CHEK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
All You Need to Know About CheckCap Ltd. (CHEK) Rating Upgrade to Buy
by Zacks Equity Research
CheckCap Ltd. (CHEK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Check-Cap Ltd. (CHEK) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Check-Cap Ltd. (CHEK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Check-Cap Ltd. (CHEK) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Check-Cap Ltd. (CHEK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Luminex (LMNX) Looks Good: Stock Adds 5.7% in Session
by Zacks Equity Research
Luminex (LMNX) shares rose nearly 6% in the last trading session, amid huge volumes.
4 Stocks to Buy at Their 52-Week Lows
by Ryan McQueeney
While many momentum-focused investors focus on buying stocks near new highs and hoping the upward trend continues, other investors find value in searching for stocks that are poised to rebound after hitting new lows. Check out these slumping stocks that could be poised for a rebound soon.
The Zacks Analyst Blog Highlights: PRA Health Sciences, Mesa Laboratories, ConforMIS, Check-Cap and Streamline Health Solutions
by Zacks Equity Research
The Zacks Analyst Blog Highlights: PRA Health Sciences, Mesa Laboratories, ConforMIS, Check-Cap and Streamline Health Solutions
5 MedTech Stocks to Buy Before Q3 Earnings
by Zacks Equity Research
The Q3 earnings season is just around the corner for the political hotspot MedTech space.